| Shoba Subramanian, MD | |
|
701 E El Camino Real, Mountain View, CA 94040-2833 | |
| (650) 934-7500 | |
| Not Available |
| Full Name | Shoba Subramanian |
|---|---|
| Gender | Female |
| Speciality | Endocrinology |
| Experience | 21 Years |
| Location | 701 E El Camino Real, Mountain View, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1942493341 | NPI | - | NPPES |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sutter Bay Medical Foundation | 4284538778 | 2941 |
News Archive
Furiex Pharmaceuticals, Inc. today confirmed that Takeda Pharmaceutical Company Limited announced that its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc. has resubmitted New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA) for alogliptin and fixed-dose combination therapy alogliptin and pioglitazone for the treatment of type 2 diabetes in adults.
The Cedars-Sinai Heart Institute has been awarded a $1.66 million, four-year grant from the National Heart, Lung and Blood Institute of the National Institutes of Health to develop a measurement system that could help doctors predict which patients could be struck by sudden cardiac arrest, a heart rhythm disturbance that causes instant death in more than 95 percent of cases.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C., today announced results from the MAGELLAN Phase 3 trial evaluating the investigational oral anticoagulant rivaroxaban for the prevention of venous thromboembolism in hospitalized patients with acute medical illnesses.
Novartis announced today that the results of the MEASURE 1 and MEASURE 2 Phase III studies for Cosentyx® (secukinumab) in ankylosing spondylitis (AS) were published in The New England Journal of Medicine (NEJM). These pivotal studies demonstrated significant clinical improvements with Cosentyx versus placebo in reducing the signs and symptoms of active AS – a long-term, painful and debilitating inflammation of the spine.
› Verified 9 days ago
| Entity Name | Sutter Bay Medical Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013950807 PECOS PAC ID: 4284538778 Enrollment ID: O20031125000909 |
News Archive
Furiex Pharmaceuticals, Inc. today confirmed that Takeda Pharmaceutical Company Limited announced that its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc. has resubmitted New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA) for alogliptin and fixed-dose combination therapy alogliptin and pioglitazone for the treatment of type 2 diabetes in adults.
The Cedars-Sinai Heart Institute has been awarded a $1.66 million, four-year grant from the National Heart, Lung and Blood Institute of the National Institutes of Health to develop a measurement system that could help doctors predict which patients could be struck by sudden cardiac arrest, a heart rhythm disturbance that causes instant death in more than 95 percent of cases.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C., today announced results from the MAGELLAN Phase 3 trial evaluating the investigational oral anticoagulant rivaroxaban for the prevention of venous thromboembolism in hospitalized patients with acute medical illnesses.
Novartis announced today that the results of the MEASURE 1 and MEASURE 2 Phase III studies for Cosentyx® (secukinumab) in ankylosing spondylitis (AS) were published in The New England Journal of Medicine (NEJM). These pivotal studies demonstrated significant clinical improvements with Cosentyx versus placebo in reducing the signs and symptoms of active AS – a long-term, painful and debilitating inflammation of the spine.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Shoba Subramanian, MD 2350 W. El Camino Real, Mountain View, CA 94040-6203 Ph: (650) 934-7500 | Shoba Subramanian, MD 701 E El Camino Real, Mountain View, CA 94040-2833 Ph: (650) 934-7500 |
News Archive
Furiex Pharmaceuticals, Inc. today confirmed that Takeda Pharmaceutical Company Limited announced that its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc. has resubmitted New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA) for alogliptin and fixed-dose combination therapy alogliptin and pioglitazone for the treatment of type 2 diabetes in adults.
The Cedars-Sinai Heart Institute has been awarded a $1.66 million, four-year grant from the National Heart, Lung and Blood Institute of the National Institutes of Health to develop a measurement system that could help doctors predict which patients could be struck by sudden cardiac arrest, a heart rhythm disturbance that causes instant death in more than 95 percent of cases.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C., today announced results from the MAGELLAN Phase 3 trial evaluating the investigational oral anticoagulant rivaroxaban for the prevention of venous thromboembolism in hospitalized patients with acute medical illnesses.
Novartis announced today that the results of the MEASURE 1 and MEASURE 2 Phase III studies for Cosentyx® (secukinumab) in ankylosing spondylitis (AS) were published in The New England Journal of Medicine (NEJM). These pivotal studies demonstrated significant clinical improvements with Cosentyx versus placebo in reducing the signs and symptoms of active AS – a long-term, painful and debilitating inflammation of the spine.
› Verified 9 days ago
Sevwandi De Silva, M.D. Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 701 E El Camino Real, Mountain View, CA 94040 Phone: 650-934-7144 | |
Dr. Gayathri Thiru, M.D Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 2490 Hospital Drive, Suite 212, Mountain View, CA 94040 Phone: 408-900-8077 Fax: 844-965-9436 | |
Dr. Shawn Mathew Jacob, MD Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 2500 Grant Rd, Mountain View, CA 94040 Phone: 650-940-7000 | |
Dr. Vibha Ramaswamy Iyengar, M.D, MPH Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 701 E El Camino Real, Mountain View, CA 94040 Phone: 650-934-7808 | |
Geoffrey Yoon, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 701 E El Camino Real, Mountain View, CA 94040 Phone: 650-404-8300 | |
Dr. David Alan Reinert, D.O. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 701 E El Camino Real, Mountain View, CA 94040 Phone: 650-934-7000 | |
Apurva Marfatia, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 701 E El Camino Real, Medical Staff, Mountain View, CA 94040 Phone: 650-934-7144 |